Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Killer cells. --- Cancer --- Immunotherapy. --- K cells --- Natural killer cells --- NK cells --- Immunocompetent cells --- Cell-mediated cytotoxicity --- Immunological aspects --- Treatment --- Immunotherapy --- Research. --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Tumors
Choose an application
This book undertakes the first large-scale analysis of women’s agency in Frank Herbert’s six-book science fiction Dune series. Kara Kennedy explores how female characters in the Bene Gesserit Sisterhood—from Jessica to Darwi Odrade—secure control and influence through five avenues of embodied agency: mind-body synergy, reproduction and motherhood, voices, education and memory, and sexuality. She also discusses constraints on their agency, tensions between individual and collective action, and comparisons with other characters including the Mentats, Bene Tleilaxu, and Honored Matres. The book engages with second-wave feminist theories and historical issues to highlight how the series anticipated and paralleled developments in the women’s liberation movement. In this context, it addresses issues regarding sexual difference and solidarity, as well as women’s demand to have control over their bodies. Kennedy concludes that the series should be acknowledged as a significant contribution to the genre as part of both New Wave and feminist science fiction. Kara Kennedy is a researcher, writer, and educator in the areas of science fiction, digital literacy, and writing. She is an avid scholar of Dune who has lectured and published on various topics including world-building. She posts literary analyses of Dune for a mainstream audience on her blog DuneScholar.com.
Philosophy --- Sociology of culture --- Sociology of the family. Sociology of sexuality --- Fiction --- American literature --- Literature --- populaire cultuur --- filosofie --- literatuur --- gender --- fantasie (verbeelding) --- America --- Women in literature. --- Feminism in literature. --- Woman (Christian theology) in literature --- Women in drama --- Women in poetry --- Feminist theory in literature --- Herbert, Frank. --- Herbert, Frank --- Kherbert, Frėnk --- הרברט, פרנק --- Herbert, Franklin Patrick, --- Science fiction, American --- History and criticism. --- Criticism and interpretation. --- Characters. --- American science fiction --- American fiction --- Fiction. --- Feminism and literature. --- Popular Culture. --- Women --- Sex. --- Fiction Literature. --- Feminist Literary Theory. --- North American Literature. --- Women's History / History of Gender. --- Gender Studies. --- Gender (Sex) --- Human beings --- Human sexuality --- Sex (Gender) --- Sexual behavior --- Sexual practices --- Sexuality --- Sexology --- Feminism --- Manners and customs --- Culture, Popular --- Mass culture --- Pop culture --- Popular arts --- Communication --- Intellectual life --- Mass society --- Recreation --- Culture --- Literature and feminism --- Literature and philosophy --- Philosophy and literature --- Metafiction --- Novellas (Short novels) --- Novels --- Stories --- Novelists --- Philosophy. --- Literatures. --- History. --- Women authors --- Theory
Choose an application
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
Medicine --- NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a
Choose an application
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
Medicine --- NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a
Choose an application
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a
Listing 1 - 5 of 5 |
Sort by
|